AUSTIN, Texas, June 4, 2024 /PRNewswire/ — The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS 2 Bio Inc. The ...
AUSTIN, Texas, Jan. 30, 2025 /PRNewswire/ -- Dr. Roger Hollis from the University of California, Los Angeles, project scientist from the laboratory of Dr. Donald Kohn, a world leader in developing ...
ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense ...
AUSTIN, Texas, June 4, 2024 /PRNewswire/ — The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS2Bio Inc. The ...
The Foundation for Angelman Syndrome Therapeutics (FAST) announced today that the non-profit organization has entered into an exclusive global collaborative research and development agreement with the ...
Ultragenyx (RARE) Pharmaceutical announced that the first patient has been dosed in the pivotal Phase 3 Aspire study, NCT06617429, evaluating the efficacy and safety of GTX-102, its investigational ...
Ultragenyx Pharmaceutical Inc. announced the dosing of the first patient in its Phase 3 Aspire study, which is investigating the safety and efficacy of GTX-102, an investigational antisense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results